Development of a New Class of Broad-Stage Antimalarial Agents [ 1/1/2021 - 12/31/2022 ]

Research Grant

Brief description In 2017, there were almost 220 million cases of malaria across 90 different countries, associated with 435,000 deaths, and with 65-70% of all malaria deaths tragically being children under the age of 5 years old. No significant progress in reducing global malaria cases has been made over the last 4 years and the need for new and better treatments remains dire. In this research and development plan, we will develop novel and safer drugs for the treatment of drug resistant malaria.

Funding Amount $729,037

Funding Scheme Development Grants

Chief Investigator Prof Jonathan Baell

Notes Development Grant